1. Search Result
Search Result
Results for "

Sirolimus

" in MedChemExpress (MCE) Product Catalog:

11

Inhibitors & Agonists

2

Fluorescent Dye

2

Biochemical Assay Reagents

2

Natural
Products

3

Isotope-Labeled Compounds

1

GMP Molecules

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-10219
    Rapamycin
    1335+ Cited Publications

    Sirolimus; AY-22989; NSC 226080

    mTOR FKBP Fungal Autophagy Endogenous Metabolite Antibiotic Bacterial Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Rapamycin (Sirolimus; AY 22989) is a potent and specific blood-brain barrier-transmissible mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .
    Rapamycin
  • HY-10219R

    Sirolimus (Standard); AY-22989 (Standard); NSC 226080 (Standard)

    Reference Standards mTOR FKBP Fungal Autophagy Endogenous Metabolite Antibiotic Bacterial Cancer
    Rapamycin (Standard) is the analytical standard of Rapamycin (HY-10219). This product is intended for research and analytical applications. Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .
    Rapamycin (Standard)
  • HY-10219S
    Rapamycin-d3
    1 Publications Verification

    Sirolimus-d3; AY-22989-d3; NSC 226080-d3

    Isotope-Labeled Compounds mTOR FKBP Autophagy Cancer
    Rapamycin-d3 is the deuterium labeled Rapamycin. Rapamycin is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1. Rapamycin is an autophagy activator, an immunosuppressant .
    Rapamycin-d3
  • HY-10219G

    Sirolimus; AY-22989; NSC 226080

    mTOR FKBP Fungal Autophagy Endogenous Metabolite Antibiotic Bacterial Infection Cancer
    Rapamycin (Sirolimus) (GMP) is Rapamycin (HY-10219) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .
    Rapamycin
  • HY-10219GL

    Sirolimus (GMP Like); AY-22989 (GMP Like); NSC 226080 (GMP Like)

    mTOR FKBP Fungal Autophagy Endogenous Metabolite Antibiotic Bacterial Cancer
    Rapamycin (Sirolimus) GMP Like is Rapamycin (HY-10219) produced by using GMP like guidelines. GMP Like small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .
    Rapamycin (GMP Like)
  • HY-10219S1

    Sirolimus-13C,d3; AY-22989-13C,d3 NSC 226080-13C,d3

    Isotope-Labeled Compounds mTOR FKBP Fungal Autophagy Endogenous Metabolite Antibiotic Bacterial Cancer
    Rapamycin- 13C,d3 (Sirolimus- 13C,d3) is the 13C and deuterium labeled Rapamycin (HY-10219) . Rapamycin is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1. Rapamycin is an autophagy activator, an immunosuppressant .
    Rapamycin-13C,d3
  • HY-101287

    Microtubule/Tubulin JNK Apoptosis Caspase Cancer
    MPT0B392, an orally active quinoline derivative, induces c-Jun N-terminal kinase (JNK) activation, leading to apoptosis. MPT0B392 inhibits tubulin polymerization and triggers induction of the mitotic arrest, followed by mitochondrial membrane potential loss and caspases cleavage by activation of JNK and ultimately leads to apoptosis. MPT0B392 is demonstrated to be a novel microtubule-depolymerizing agent and enhances the cytotoxicity of sirolimus in sirolimus-resistant acute leukemic cells and the multidrug resistant cell line .
    MPT0B392
  • HY-W781875

    mTOR Cancer
    Sirolimus isomer C is an impurity of Rapamycin (Sirolimus) (HY-10219) .
    Sirolimus isomer C
  • HY-W765245

    Sirolimus-13C,d3-1; AY-22989-13C,d3-1

    Isotope-Labeled Compounds Fungal mTOR Bacterial Autophagy Endogenous Metabolite FKBP Antibiotic Cancer
    Rapamycin- 13C,d3-1 (Sirolimus- 13C,d3-1) is the deuterium labeled and 13C-labeled Rapamycin (HY-10219). Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .
    Rapamycin-13C,d3-1
  • HY-181873

    Sirolimus-butyl ester

    Drug Derivative Cancer
    Rapamycin-butyl ester (Sirolimus-butyl ester) (Compound 9) is a derivative of Rapamycin (HY-10219). Rapamycin-butyl ester exhibits antiproliferative effects against liver cancer cells and renal cancer cells. Rapamycin-butyl ester can be used in research related to liver cancer and renal cancer .
    Rapamycin-butyl ester
  • HY-101287R

    Microtubule/Tubulin Reference Standards JNK Apoptosis Caspase Cancer
    MPT0B392 (Standard) is the analytical standard of MPT0B392 (HY-101287). This product is intended for research and analytical applications. MPT0B392, an orally active quinoline derivative, induces c-Jun N-terminal kinase (JNK) activation, leading to apoptosis. MPT0B392 inhibits tubulin polymerization and triggers induction of the mitotic arrest, followed by mitochondrial membrane potential loss and caspases cleavage by activation of JNK and ultimately leads to apoptosis. MPT0B392 is demonstrated to be a novel microtubule-depolymerizing agent and enhances the cytotoxicity of sirolimus in sirolimus-resistant acute leukemic cells and the multidrug resistant cell line .
    MPT0B392 (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: